Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022607 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by California Cancer Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Study locations
NCT00022607: Completed Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by California Cancer Consortium.
NCT00022607 is a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by California Cancer Consortium. The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022607, a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by California Cancer Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. It is not yet known whether bevacizumab works better with or without thalidomide for multiple myeloma. PURPOSE: This randomized phase II trial is to see if bevacizumab works better with or without thalidomide in treating patients who have relapsed or refractory multiple myeloma.
Conditions Studied
Interventions
- BIOLOGICAL bevacizumab
- DRUG thalidomide
Study Locations (4)
California
- City of Hope Comprehensive Cancer Center - Duarte
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- University of California Davis Cancer Center - Sacramento
Illinois
- University of Chicago Cancer Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00022607 record still lists
NCT00022607 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which bevacizumab is the first listed.
NCT00022607 reports a single indexed study location in California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00022607 about?
NCT00022607 is a clinical study titled "Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Thalidomide may stop the growth of cancer cells by st...
What is the current status of trial NCT00022607?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-01. Estimated completion is 2006-05.
What conditions does trial NCT00022607 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00022607?
The interventions under investigation include: bevacizumab (BIOLOGICAL), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00022607?
This trial is sponsored by California Cancer Consortium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022607 being conducted?
This trial has 4 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
COMPLETED · Phase 2
-
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
COMPLETED · Phase 2
-
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
COMPLETED · Phase 2
-
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
COMPLETED · Phase 2
-
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
COMPLETED · Phase 2
-
Campath-1H + FK506 and Methylprednisolone for GVHD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia